Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax
Provided By GlobeNewswire
Last update: Jul 10, 2023
-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones
-- Next procurement expected in early 2024
